中新网9月20日电 国家发改委今日在其官方网站上公布《关于印发进一步加强药品安全信用体系建设工作的指导意见》。意见要求，严格落实药品生产和经营主体责任，加强失信行为的联合惩戒，使“黑牌”药品生产经营企业及个人“一处失信、处处受限”。 

Beijing September 20, the national development and reform commission today announced in its official website[About print and distribute further strengthen drug safety credit system construction work instruction opinion].Opinion request,Strictly implement pharmaceutical production and management main body responsibility,Strengthen discreditable behavior of joint discipline,make"Black card"Pharmaceutical production business enterprise and individual"One place break faith/Everywhere limited". 

　　意见要求，建立健全信用分类监管机制。以药品企业静态登记信息和动态监管信息为基础，按照守法诚信度、行业风险度、区域重要度和动态警示度指标体系，对药品企业信用实现科学多维分类，建立守信企业激励机制、警示企业预警机制、失信企业惩戒机制、严重失信企业淘汰机制。对进入被吊销营业执照或取消药品生产许可证的药品企业数据库和一人有限公司数据库的企业及其法定代表人在全国范围内锁定，使“黑牌”药品生产经营企业及个人“一处失信、处处受限”。

Opinion request,Setting up and perfecting the credit classified supervision mechanism.Medicine enterprise static registration information and dynamic regulatory information as the foundation,According to the law-abiding integrity/Industry risk level/Regional important degree and dynamic warning degree index system,For pharmaceutical enterprise credit to realize scientific multidimensional classification,Establish and trustworthy enterprise incentive mechanism/Warning enterprise early warning mechanism/Break faith enterprise disciplinary mechanism/Serious break faith enterprise selection mechanism.To enter the business license is revoked or cancelled pharmaceutical production license drug enterprise database and one co., LTD. Database of enterprise and its legal representative in the nationwide lock,make"Black card"Pharmaceutical production business enterprise and individual"One place break faith/Everywhere limited".

　　意见强调，严格落实药品生产和经营主体责任，加强失信行为的联合惩戒。在实现行业内、地区内信用信息互联互通的基础上，加快建立药品安全失信记录档案。对人民群众日常生活造成危害、对药品行业健康发展和社会稳定构成影响的药品生产和经营主体的失信行为，不仅要在各级新闻媒体和网站上进行披露和曝光，还要将失信主体列为日常监督、重点监测或抽查的重点，并撤销其已有荣誉称号，依法在行政许可、资质等级评定、评优评先、享受政府补贴、投资项目核准，以及信贷投放等方面予以惩戒，同时实施法律、法规、规章规定的其他限制措施。

Opinion emphasize,Strictly implement pharmaceutical production and management main body responsibility,Strengthen discreditable behavior of joint discipline.In the industry in realization/Area credit information on the basis of interconnection and interflow,To speed up the establishment of drug safety break faith record files.The People's Daily life to cause damage/Pharmaceutical industry to the healthy development and social stability to constitute the influence of drug production and management main body discreditable behavior,At all levels should not only in news media and website for disclosure and exposure,And he will break faith subject as daily supervision/The focus of the key monitoring or selective examination,And revoke its existing honorary title,In accordance with the administrative licensing in/Qualification rating/PingXian assessment/Enjoy government subsidies/Investment projects approved,And credit availability, etc to retribution,At the same time the implementation of legal/regulations/The provisions of rules formulated by the other restrictions.